Literature DB >> 17114207

Strategies and outcomes of PGD of familial adenomatous polyposis.

C Moutou1, N Gardes, J-C Nicod, S Viville.   

Abstract

Owing to adult onset of hereditary cancer, prenatal diagnosis (PND) raises numerous ethical issues on the acceptability to terminate an affected pregnancy (TOP). PND for these disorders is often considered as unacceptable by couples as well as geneticists and legal or ethical authorities, but preimplantation genetic diagnosis (PGD), even if subject to controversy, seems to be a more acceptable option. Therefore, many couples, who do not want to transmit their cancer to their children, consider PGD as their only reproductive option. This article describes our experience of PGD for familial adenomatous polyposis (FAP). Twelve couples were referred between 2000 and 2005. We developed PGD tests to detect the mutation alone, but we rapidly set up multiplex PCR combining mutation detection and indirect diagnosis. Finally, we set up duplex and triplex indirect diagnoses to be able to offer a PGD, whatever mutation was involved in familial cases. PGD strategies were based on (i) a new double allele-specific PCR approach (D-ARMS) allowing the detection of the wild-type and mutated allele; (ii) PCR fragments sizing and (iii) restriction length polymorphisms. For the 12 referrals, we developed eight tests, and 11 cycles have been performed for four couples, resulting in eight embryo transfers and five pregnancies, with the birth of one healthy boy and two ongoing pregnancies. We are now able to propose PGD to most couples at risk of transmitting FAP to their offspring, whether the mutation is familial or occurred de novo.

Entities:  

Mesh:

Year:  2006        PMID: 17114207     DOI: 10.1093/molehr/gal102

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  8 in total

1.  Singling out genetic disorders and disease.

Authors:  Martine De Rycke
Journal:  Genome Med       Date:  2010-10-06       Impact factor: 11.117

2.  Views of internists towards uses of PGD.

Authors:  Robert Klitzman; Wendy Chung; Karen Marder; Anita Shanmugham; Lisa J Chin; Meredith Stark; Cheng-Shiun Leu; Paul S Appelbaum
Journal:  Reprod Biomed Online       Date:  2012-11-21       Impact factor: 3.828

3.  PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers.

Authors:  Marion Drüsedau; Jos C Dreesen; Inge Derks-Smeets; Edith Coonen; Ron van Golde; Jannie van Echten-Arends; Peter M M Kastrop; Marinus J Blok; Encarna Gómez-García; Joep P Geraedts; Hubert J Smeets; Christine E de Die-Smulders; Aimée D Paulussen
Journal:  Eur J Hum Genet       Date:  2013-03-27       Impact factor: 4.246

4.  Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes.

Authors:  Amanda C Brandt; Matthew L Tschirgi; Kaylene J Ready; Charlotte Sun; Sandra Darilek; Jacqueline Hecht; Banu K Arun; Karen H Lu
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

5.  Attitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch syndrome.

Authors:  Akriti Dewanwala; Anu Chittenden; Margery Rosenblatt; Rowena Mercado; Judy E Garber; Sapna Syngal; Elena M Stoffel
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

Review 6.  Small bowel polyposis syndromes.

Authors:  Nadir Arber; Menachem Moshkowitz
Journal:  Curr Gastroenterol Rep       Date:  2011-10

7.  Attitudes toward genetic testing in childhood and reproductive decision-making for familial adenomatous polyposis.

Authors:  Kirsten F L Douma; Neil K Aaronson; Hans F A Vasen; Senno Verhoef; Chad M Gundy; Eveline M A Bleiker
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246

Review 8.  Familial adenomatous polyposis.

Authors:  Elizabeth Half; Dani Bercovich; Paul Rozen
Journal:  Orphanet J Rare Dis       Date:  2009-10-12       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.